gdc
Author Guidelines Submit Your Art
Subscribe

FDA Approvals, News & Updates

Rezlidhia FDA Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
LeukemiaFDA Approvals, News & Updates
Rezlidhia FDA Approved for Patients with Relapsed or Refractory Acute Myeloid Leukemia and IDH1 Mutation
December 2022 Vol 8 No 6
Adcetris Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
FDA Approvals, News & UpdatesLymphoma
Adcetris Now FDA Approved for Pediatric Patients with Classical Hodgkin Lymphoma
December 2022 Vol 8 No 6
Elahere FDA Approved for Patients with FRα-Positive, Platinum-Resistant Ovarian Cancer
Ovarian CancerFDA Approvals, News & Updates
Elahere FDA Approved for Patients with FRα-Positive, Platinum-Resistant Ovarian Cancer
December 2022 Vol 8 No 6
Imjudo New Immunotherapy FDA Approved with Imfinzi Immunotherapy for Patients with Liver Cancer
FDA Approvals, News & UpdatesLiver Cancer
Imjudo New Immunotherapy FDA Approved with Imfinzi Immunotherapy for Patients with Liver Cancer
December 2022 Vol 8 No 6
Imjudo plus Imfinzi and Chemotherapy FDA Approved for Patients with Metastatic Lung Cancer
FDA Approvals, News & UpdatesLung Cancer
Imjudo plus Imfinzi and Chemotherapy FDA Approved for Patients with Metastatic Lung Cancer
December 2022 Vol 8 No 6
Libtayo plus Chemotherapy Now FDA Approved for Advanced Lung Cancer without Genomic Alterations
FDA Approvals, News & UpdatesLung Cancer
Libtayo plus Chemotherapy Now FDA Approved for Advanced Lung Cancer without Genomic Alterations
December 2022 Vol 8 No 6
Tecvayli Received FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
Multiple MyelomaFDA Approvals, News & Updates
Tecvayli Received FDA Approval for Patients with Relapsed or Refractory Multiple Myeloma
December 2022 Vol 8 No 6
Enhertu First Drug Approved for Patients with HER2-Low Breast Cancer
FDA Approvals, News & UpdatesBreast Cancer
Enhertu First Drug Approved for Patients with HER2-Low Breast Cancer
October 2022 Vol 8 No 5
Nubeqa Approved for Men with Metastatic Hormone-Sensitive Prostate Cancer
FDA Approvals, News & UpdatesProstate Cancer
Nubeqa Approved for Men with Metastatic Hormone-Sensitive Prostate Cancer
October 2022 Vol 8 No 5
Lytgobi Newest Drug Approved for Patients with FGFR2-Positive Cholangiocarcinoma
FDA Approvals, News & UpdatesCholangiocarcinoma
Lytgobi Newest Drug Approved for Patients with FGFR2-Positive Cholangiocarcinoma
October 2022 Vol 8 No 5
Page 1 of 16
Results 1 - 10 of 160

Subscribe to Conquer™: the journey informed™

Receive timely cancer news & updates, patient stories, and more.

Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest
Other Interests